What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?

Hi bugg log : Thank you for the question—this is an important consideration. Our primary focus is to bring our product to market successfully and build a sustainable, profitable company. By demonstrating real clinical value and commercial traction, we believe this will naturally open the door to multiple exit opportunities over time. As we scale, this could include a potential IPO or a strategic merger or acquisition with a major player in the radiotherapy or medical device space. Historicall...

I am wondering what makes you different then other companies saying they can help cure cancer that is raising now? is anybody on your team fully committed to this company? out of 3 I see. 2 are college professors and one is a founder and CEO of his own company.

Hi John, Thank you for the thoughtful question—this is an important point, and I’m glad you raised it. What differentiates TibaRay is that we are not approaching cancer treatment as a concept—we are building the core enabling technology for next-generation radiotherapy. Specifically, our proprietary linear accelerator platform is designed to deliver ultra-high dose rate (FLASH) radiation, which has the potential to significantly reduce damage to healthy tissue while maintaining tumor control....

What are the relationships between "Vita Imaging" and "TibaRay" financially, physically, legally, and control wise? How large are the engineering teams? Operations teams? Have either of these groups integrated, qualified, or produced anything? I see a lot of concept and pontif...

Great questions—happy to clarify. Vita Imaging and TibaRay are separate companies with no shared ownership or finances. I lead both, but each has its own team, investors, and operations. Strategically, they are complementary: Vita focuses on cancer detection, while TibaRay focuses on treatment. We have dedicated engineering and operations teams working on real hardware and systems—not just concepts. This includes active development, testing, and integration work. We are well beyond the concep...

If this entity is losing over $3M per year, when do you plan to become profitable?

Hello William: In our space, it’s normal to operate at a loss during the development phase—medical device companies typically take 3–7+ years to mature R&D due to technical complexity as well as regulatory and clinical requirements . The key difference with TibaRay is that we have already largely de-risked the core technology and are now transitioning into commercial deployment through partners and early systems. With commercialization underway, our focus is on scaling revenue, with the g...

thanks for swift response! Saturday morning I am making a ton of business investments. few more questions what is your moat? there is a company raising now called CancerVax(stood out to me) I can't tell between you and them which is better. can you tell me the key difference b...

Great question—and you’re right, both stories sound compelling. The key difference is that we are solving different problems: - TibaRay: advanced radiation platform (hardware + physics) to directly treat tumors - CancerVax: early-stage biotech developing a cancer vaccine to train the immune system Our moat is in deep engineering and system integration—building high-performance linacs, manufacturing them, and integrating into clinical systems. This is very hard to replicate and has a clearer p...

Invest in TibaRay, Inc.

Patented Radiotherapy Technology Designed to Help Cure Cancer in a FLASH™

FIRST GOAL HIT (You can still invest)

$978,453

raised from 138+ investors

INVEST

min $500

INVESTMENT TERMS

Preferred Stock

$60M pre-money valuation $5.28 per share

tibaray.com

Fremont, CA

Notable Angel B2B Healthcare Biotech VC-Backed

Highlights

VC-Backed

Raised $250K or more from a venture firm

Repeat Founder

Started a prior company with $2M+ in funding or revenue

Robust IP portfolio with 20+ issued and pending patents on next-generation radiotherapy technology.

Partnership with an innovative radiotherapy technology provider to integrate core technology.

$9 billion global radiotherapy market with adjacent multi-billion dollar applications.

24,000 sq ft fully integrated Silicon Valley facility for prototyping, testing, and production.

Featured Investors

Team

Pitch Deck

1 / —

Revolutionizing Cancer Treatment with FLASH

TibaRay is building an ultra-fast, ultra-precise radiotherapy platform to dramatically improve cancer outcomes while reducing side effects, cost, and treatment time.

We are not just improving cancer therapy. We are redefining what is curable.

The Solution

TibaRay enables FLASH—delivering treatment in a fraction of a second instead of minutes, over 400X faster than today’s state-of the art technology. Recent research shows that this can greatly reduce normal tissue damage, allowing for more curative treatments. In addition, twice as many patients can be treated at reduced costs.

FLASH radiobiology is a new scientific discovery showing that ultra-rapid radiation can spare healthy tissue without compromising tumor kill. TibaRay's advances in accelerator physics, RF systems, and beam control now make conformal FLASH clinically feasible for the first time.

The Tech Powering PHASER

Over the past decade TibaRay has been developing revolutionary linear accelerator and RF component technologies invented at Stanford University. More than $27 million has been invested, including more than $13 million in non-dilutive highly competitive federal grants. These technologies are commercial today and will power PHASER in the near future.

Our Galactica linac has been designed into the Leo Cancer Care treatment system, marking the first TibaRay Inside™ commercial partnership integrating Galactica into Leo’s complete treatment platform.

Market Opportunity

We are initially focusing on cancer care and treating patients with tumors anywhere in the body.

The cancer therapy market is $300 billion overall with radiotherapy being $9 billion (currently with 6-8% CAGR).

In addition, there’s $20 billion in opportunities for applications in other major illnesses:

Cardiac arrhythmias (e.g., ventricular tachycardia*, atrial fibrillation)
Pulmonary emphysema*
Functional neurologic conditions
Arthritis & inflammatory conditions
Others (potentially Alzheimer’s, etc.)…

*First human clinical trials of focused radiotherapy performed by Dr. Bill Loo

Business Model

Our near-term revenue will be generated by delivering our linacs into the TibaRay Inside™ markets, including healthcare, non-destructive testing, and border security applications.

Our long-term objective is full commercialization and deployment of the PHASER system, leveraging our proprietary accelerator technology to address large global markets and create multi-billion-dollar revenue opportunities.